Sökning: (WFRF:(Fryknäs Mårten)) srt2:(2020-2024) > Melphalan flufenami...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04248naa a2200481 4500 | |
001 | oai:DiVA.org:uu-457555 | |
003 | SwePub | |
008 | 211109s2021 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-4575552 URI |
024 | 7 | a https://doi.org/10.1016/j.bonr.2021.1010982 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Byrgazov, Konstantinu Oncopeptides AB, Stockholm, Sweden.4 aut |
245 | 1 0 | a Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes |
264 | 1 | b Elsevier,c 2021 |
338 | a print2 rdacarrier | |
520 | a Myeloma bone disease is a major complication in multiple myeloma affecting quality of life and survival. It is characterized by increased activity of osteoclasts, bone resorbing cells. Myeloma microenvironment promotes excessive osteoclastogenesis, a process of production of osteoclasts from their precursors, monocytes. The effects of two anti-myeloma drugs, melphalan flufenamide (melflufen) and melphalan, on the activity and proliferation of osteoclasts and their progenitors, monocytes, were assessed in this study. In line with previous research, differentiation of monocytes was associated with increased expression of genes encoding DNA damage repair proteins. Hence monocytes were more sensitive to DNA damage-causing alkylating agents than their differentiated progeny, osteoclasts. In addition, differentiated progeny of monocytes showed increased gene expression of immune checkpoint ligands which may potentially create an immunosuppressive microenvironment. Melflufen was ten-fold more active than melphalan in inhibiting proliferation of osteoclast progenitors. Furthermore, melflufen was also superior to melphalan in inhibition of osteoclastogenesis and bone resorption. These results demonstrate that melflufen may exert beneficial effects in patients with multiple myeloma such as reducing bone resorption and immunosuppressive milieu by inhibiting osteoclastogenesis. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Hematologi0 (SwePub)302022 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Hematology0 (SwePub)302022 hsv//eng |
653 | a Osteoclastogenesis | |
653 | a Bone resorption | |
653 | a Melflufen | |
653 | a Melphalan | |
700 | 1 | a Lind, Thomas,c Docent,d 1965-u Uppsala universitet,Klinisk farmakogenomik och osteoporos4 aut0 (Swepub:uu)tli08750 |
700 | 1 | a Rasmusson, Annica J.u Uppsala universitet,Institutionen för medicinsk biokemi och mikrobiologi,Klinisk farmakogenomik och osteoporos,Cervenka: Psykiatri4 aut0 (Swepub:uu)annijaco |
700 | 1 | a Andersson, Claesu Uppsala universitet,Cancerfarmakologi och beräkningsmedicin4 aut0 (Swepub:uu)cland109 |
700 | 1 | a Slipicevic, Anau Oncopeptides AB, Stockholm, Sweden.4 aut |
700 | 1 | a Lehmann, Fredriku Oncopeptides AB, Stockholm, Sweden.4 aut |
700 | 1 | a Gullbo, Joachimu Uppsala universitet,Cancerfarmakologi och beräkningsmedicin,Experimentell och klinisk onkologi4 aut0 (Swepub:uu)joacgull |
700 | 1 | a Melhus, Håkanu Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Klinisk farmakogenomik och osteoporos,Science for Life Laboratory, SciLifeLab4 aut0 (Swepub:uu)hakamelh |
700 | 1 | a Larsson, Rolfu Uppsala universitet,Cancerfarmakologi och beräkningsmedicin,Klinisk immunologi4 aut0 (Swepub:uu)rolflars |
700 | 1 | a Fryknäs, Mårtenu Uppsala universitet,Cancerfarmakologi och beräkningsmedicin4 aut0 (Swepub:uu)mafry516 |
710 | 2 | a Oncopeptides AB, Stockholm, Sweden.b Klinisk farmakogenomik och osteoporos4 org |
773 | 0 | t Bone Reportsd : Elsevierg 15q 15x 2352-1872 |
856 | 4 | u https://doi.org/10.1016/j.bonr.2021.101098y Fulltext |
856 | 4 | u https://doi.org/10.1016/j.bonr.2021.101098 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-457555 |
856 | 4 8 | u https://doi.org/10.1016/j.bonr.2021.101098 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy